The Future of Electrification Conference Returns for its Fourth Year
16.1.2025 16:00:00 EET | Business Wire | Press release
ZAPI GROUP, a global leader in vehicle electrification, announces it will host its fourth Future of Electrification virtual conference on February 26-27, 2025. Building on the success of previous years, this year's conference will examine trends in the worldwide shift toward electrification, challenges and opportunities across different geographical regions, and the latest innovations driving adoption and transformation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250116503457/en/
ZAPI GROUP’s Future of Electrification 2025 virtual conference takes place on February 26-27. (Graphic: Business Wire)
Presented by ZAPI GROUP, an electrification leader since 1975, the conference will provide insights into market dynamics, technology, and regulatory factors shaping the electrification movement. Centered on the theme “Innovating for Change,” presenters will share leadership expertise in the industrial electrification space, discuss the impact of battery technology in the adoption of electrification, examine challenges in the evolving global trade landscape, and more.
“The past year has been marked by significant technological advancements and geopolitical uncertainty, making the ability to adapt and innovate crucial. Our customers, partners, and industry peers have shown remarkable resilience and have overcome numerous challenges in this dynamic landscape,” said Lloyd Gomm, Global Marketing Director for ZAPI GROUP. “We are thrilled to host our fourth annual virtual event as a way to discuss these realities with other leaders in electrification and advance the global electrification movement in industrial, commercial, and utility vehicles.”
This year's dynamic program features keynote presentations from acclaimed technology and innovation expert Paulina Modlitba and Dr. Giorgio Rizzoni, Professor of Mechanical and Aerospace Engineering and The Ford Motor Company Chair in Electromechanical Systems at Ohio State University. Presenters from leading organizations such as Volvo CE, Jungheinrich, Bastion Solutions, and Infineon join the ZAPI GROUP team to explore challenges and opportunities in the current electrification landscape. Sara Jensen, Executive Editor of Power & Motion, returns this year, bringing her experience and perspective across industries as a moderator for some of the event’s panel discussions.
Free registration for The Future of Electrification 2025 is now open. Please visit www.futureofelectrification.org.
About ZAPI GROUP
ZAPI GROUP is engineering the transition to an all-electric future with a highly integrated product portfolio, including motion controllers, electric motors, high-frequency battery chargers, and autonomous navigation software for application in full-electric and hybrid vehicles. As a global electrification leader with deep systems experience, leading innovations, and an obsession with driving customers' success, ZAPI GROUP now counts more than 1700 employees worldwide with total annual revenue of more than 700 million US dollars.
For more information, visit www.zapigroup.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250116503457/en/
Contacts
Media Contact
AnnMarie Carson, Communiqué PR
Phone: (206) 282-4923 ext. 119
Email: zapigrouppr@communiquepr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 16:00:00 EEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 15:00:00 EEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 15:00:00 EEST | Press release
The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom